Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Mar 17, 2023

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases...

Mar 6, 2023

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases...

Feb 21, 2023

—ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis— TEL AVIV, Israel

Jan 3, 2023

—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments— TEL AVIV, Israel, Jan. 3, 2023...

All News

Stock Info
NASDAQCMMB
Events
Thursday, March 30, 2023
7:00am EDT

Format: Virtual management presentation and 1-on-1 investor meetings

Presentation Date: Thursday, March 30, 2023

Presentation Time: On-demand starting at 7:00 am ET

Registration/Information: lk@hcwco.com

To request a virtual 1-on-1 meeting with Chemomab management, investors should email meetings@hcwco.com.

Friday, March 31, 2023
8:00am - 9:00am EDT

Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.  

Conference Call Access via Telephone

US Investors:

+1 (877) 407-9208

International Investors:

+1 (201) 493-6784

Conference Passcode:

#13735392 

 

Or click on Call me™ for instant telephone access to the event

All Events

Featured Presentations

Download

Chemomab Corporate Overview - March 2023

 

Annual Report

Download

Chemomab 2021 Annual Report